Allergic Conjunctivitis
Conditions
Interventions
Ocular administration of SJP-0049, Placebo, or reference drug
Sponsors
Omatsu Kazunori
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Aged 18 years or older at the time of Informed Consent (any gender) Live in Japan Have a history of allergic conjunctivitis. Meet the other protocol-specified inclusion criteria
Exclusion criteria
Exclusion criteria: -Need to wear contact lens during the study -Have a history of ocular surgery during the period specified in protocol, or scheduled surgery during the study -Have a history of punctal occlusion during the period specified in protocol, or schedule during the study -Have participated in another clinical trial and received investigational drug during the period specified in protocol, or scheduled during the study -Have a use of prohibited concomitant medications during the period specified in protocol, or unable to discontinue using or anticipate using during the study -Have active ophthalmic disease other than allergic conjunctivitis -Have known history of hypersensitivity to any of the study drug ingredients -Pregnant, potentially pregnant, lactating or intending to become pregnant. Unable to obtain a consent to practice adequate contraception during the study -Unable to obtain a consent to practice adequate contraception and not to donate sperm during the study -Have judged that it is inappropriate to participate in this study by investigator -Meet the other protocol-specified exclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Subjective ocular symptom score | — |
Secondary
| Measure | Time frame |
|---|---|
| -Subjective ocular symptom score and objective ocular findings score -Safety | — |
Contacts
Public Contactdivision Clinical
Senju Pharmaceutical Co., Ltd.
Outcome results
None listed